1. JAK Inhibitors for Treatment of Psoriasis: Focus on Selective TYK2 Inhibitors

   • Miguel Nogueira
   • Luis Puig
   • Tiago Torres

   Current Opinion 04 February 2020 Pages: 341 - 352

   

2. The Rise and Fall “ing” of the HDL Hypothesis

   • Julien J. Feghaly
   • Arshag D. Mooradian

   Current Opinion 04 February 2020 Pages: 353 - 362

3. Treating Pain in Diabetic Neuropathy: Current and Developmental Drugs

   • Uazman Alam
   • Gordon Sloan
   • Solomon Tesfaye

   Review Article 10 February 2020 Pages: 363 - 384

4. Pharmacological Prevention of Postoperative Recurrence in Crohn’s Disease

   • Lucine Vuitton
   • Laurent Peyrin-Biroulet

   Review Article 13 February 2020 Pages: 385 - 399

   

5. Human Epidermal Growth Factor Receptor 2 (HER2) in Advanced Gastric Cancer: Current Knowledge and Future Perspectives

   • Juliette Palle
   • Adrien Rochand
   • Aziz Zaanan

   Review Article 19 February 2020 Pages: 401 - 415

   

6. Lumateperone: First Approval

   • Hannah A. Blair

   ADISINSIGHT REPORT 14 February 2020 Pages: 417 - 423

   

7. Lemborexant: First Approval

   • Lesley J. Scott

   AdisInsight Report 24 February 2020 Pages: 425 - 432

   

8. Avapritinib: First Approval

   • Sohita Dhillon

   AdisInsight Report 25 February 2020 Pages: 433 - 439

   

9. Sodium Oligomannate: First Approval

   • Yahiya Y. Syed

   AdisInsight Report 04 February 2020 Pages: 441 - 444

   

10. Correction to: Sodium Oligomannate: First Approval

    • Yahiya Y. Syed

    Correction 24 February 2020 Pages: 445 - 446

    

11. Correction to: Pexidartinib: First Approval

    • Yvette N. Lamb

    Correction Open access 28 February 2020 Pages: 447 - 447